Investor Presentaiton

GLOSSARY OF ABBREVIATIONS Takeda Regional Abbreviations: DS CN: China; EU: Europe; JP: Japan; US: United States of America DU AATD-LD a1-antitrypsin deficiency associated liver disease Dx Dravet syndrome duodenal ulcer Diagnosis LCM lifecycle management PK LGS Lennox-Gastaut syndrome PMDA pharmacokinetics Japan's Pharmaceuticals and Medical Devices Agency mAb monoclonal antibody POC proof of concept ADC antibody drug conjugate EE H erosive esophagitis healing MAOB monoamine oxidase B POGD ADHD attention deficit hyperactivity disorder EE M erosive esophagitis maintenance MDD major depressive disorder PONV AHA acquired hemophilia A EGFR epidermal growth factor receptor MG myasthenia gravis PRIME ALK anaplastic lymphoma kinase post-operative gastrointestinal dysfunction postoperative nausea and vomiting Priority medicines scheme by EMA EMA European Medicines Agency MLD metachromatic leukodystrophy PTCL ALCL anaplastic large-cell lymphoma peripheral T-cell lymphoma FDA the U.S. Food & Drug Administration MM multiple myeloma ALL acute lymphocytic leukemia FL front line PTH parathyroid hormone MMN multifocal motor neuropathy AML acute myeloid leukemia FSI first subject in R/R relapsed/refractory NBE New Biological Entity ASCT autologous stem cell transplant FY fiscal year RCC renal cell cancer NCE New Chemical Entity ARD acid-related diseases GERD gastroesophageal reflux disease RTK receptor tyrosine kinase ND newly diagnosed AVA Advanced Vial Access GI BBB blood brain barrier GU 29 gastrointestinal RTU ready to use NDA new drug application gastric ulcer SALCL Neg Negative BLA biologics license application GvHD graft versus host disease SBS systemic anaplastic large cell lymphoma short bowel syndrome NERD non-erosive reflux disease BMA bradykinin mediated angioedema HAE hereditary angioedema SC subcutaneous formulation NHL BTD breakthrough therapy designation non-Hodgkin lymphoma H2H head-to-head SCD sickle cell disease CAR-T chimeric antigen receptor-T NK natural killer HemA hemophilia A SCT CD Crohn's disease NME new molecular entity stem cell transplant HL Hodgkin lymphoma SID CHMP Committee for Medicinal Products for Human Use NMPA National Medical Products Administration secondary immunodeficiency HSCT hematopoietic stem cell transplant chronic inflammatory demyelinating NSCLC CIDP IBD poly radiculoneuropathy inflammatory bowel disease non-small cell lung cancer SLE systemic lupus erythematosus NSCT sq CLL chronic lymphocytic leukemia IgAN immunoglobulin A nephropathy non stem cell transplant squamous STING CML chronic myeloid leukemia H IH idiopathic hypersomnia NT1 or 2 CMV cytomegalovirus INCAT Inflammatory Neuropathy Cause and Treatment disability score ORR narcolepsy Type 1 or 2 overall response rate stimulator of interferon genes SUMO small ubiquitin-related modifier CNS central nervous system OSA obstructive sleep apnea TCE T-cell engager IND investigational new drug CPF complex perianal fistulas PARP poly (ADP-ribose) polymerase TESD treatment emergent sexual dysfunction iNHL indolent non-Hodgkin's lymphoma CRL complete response letter PAS prior approval supplement TKI ITP Immune thrombocytopenic purpura CRPC Castrate-resistant prostate cancer PCAB potassium competitive acid blocker TREM2 iTTP immune thrombotic thrombocytopenic purpura CTCL cutaneous T-cell lymphoma PCD protein C deficiency UC IV intravenous CTTP congenital thrombotic thrombocytopenic purpura PEX plasma exchange VCD tyrosine kinase inhibitor triggering receptor expressed on myeloid cells 2 ulcerative colitis virologically confirmed dengue iPSC induced pluripotent stem cells DEE developmental and epileptic encephalopathies Philadelphia chromosome-positive acute L-ASA low dose aspirin Ph+ ALL vWD von Willebrand disease DLBCL diffuse large B-cell lymphoma lymphoblastic leukemia VWF von Willebrand factor LSD lysosomal storage disorder PID primary immunodeficiency DOAC direct oral anti-coagulation 20 20

View entire presentation